Breaking

Acting FBI Director Paul Abbate retires just minutes before Trump takes office: report
Second acts: President Trump makes historic comeback
Trump’s second inaugural address was a triumph for him, and for his supporters
High-profile Dems warned Biden against preemptive pardons before giving Fauci, Milley passes
Dems promise to ‘stand up to’ Trump but laud ‘peaceful transfer of power’ after speech
Mark Milley pardoned: General at center of Afghanistan withdrawal predicted it wouldn’t be a Saigon moment
Trump vows ‘new era of national success,’ says America’s ‘decline is over’ in inaugural address
Mexican border town declares state of emergency as Trump pledges mass deportations

Business
Politics
Investing
World
Search for:

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

December 20, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Lode Gold Confirms Geology Consistent to Adjacent Puma/Kinross in New Brunswick: Gold Mineralized Rhyolites

January 20, 2025

Laguna Verde Resource Update

January 20, 2025

Ramp Metals Confirms New “Rush” Copper Discovery, Announces Mobilization for Geophysics Ahead of Drill Program

January 20, 2025

Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (1,349)
- Investing (3,555)
- Politics (5,297)
- World (4,783)

Disclaimer: usfinanceinsider.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest Posts

Copyright © 2025 usfinanceinsider.com | All Rights Reserved

Top

Business
Politics
Investing
World

Type above and press Enter to search. Press Esc to cancel.